Robert B. Bazemore - 16 Dec 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Reporting relationship: Director
Issuer ticker: AKTX
Reported as of: 16 Dec 2025
Net transaction value: +$62,499
SEC form: 4
Accepted by SEC: 18 Dec 2025, 21:56:12 UTC
Prior SEC filing: 23 Jun 2025
Next SEC filing: 26 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Abizer Gaslightwala, as Attorney-in-Fact

Key filing fact

Robert B. Bazemore filed Form 4 for Akari Therapeutics Plc (AKTX) on 18 Dec 2025.

Key facts

This page summarizes Robert B. Bazemore's Form 4 filing for Akari Therapeutics Plc (AKTX).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 18 Dec 2025, 21:56.

Change

Previous filing in this sequence was filed on 23 Jun 2025.
Current net transaction value: +$62,499.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001620152 Primary reporting owner

Bazemore Robert B

Relationship: Director
Address: C/O AKARI THERAPEUTICS PLC, 401 EAST JACKSON STREET, SUITE 3300, TAMPA
Signature: /s/ Abizer Gaslightwala, as Attorney-in-Fact
Signature date: 18 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKTX transaction Derivative

Warrants to purchase American Depositary Shares ("ADRs")

Purchase

Transaction value
Shares: +123,731
Change %
Price
Shares after: 123,731
Date: 16 Dec 2025
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 123,731
Exercise price: $0.3883
Footnotes: F1, F2, F3, F4

AKTX transaction Derivative

Pre-Funded Warrants to purchase ADRs

Purchase

Transaction value: $50,000
Shares: +123,731
Change %
Price: $0.4041
Shares after: 123,731
Date: 16 Dec 2025
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 123,731
Exercise price: $0.000000
Footnotes: F1, F2, F3, F4, F7

AKTX transaction Derivative

Warrants to purchase ADRs

Purchase

Transaction value
Shares: +30,932
Change %
Price
Shares after: 30,932
Date: 16 Dec 2025
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 30,932
Exercise price: $0.3883
Footnotes: F1, F5, F6

AKTX transaction Derivative

Pre-Funded Warrants to purchase ADRs

Purchase

Transaction value: $12,500
Shares: +30,932
Change %
Price: $0.4041
Shares after: 30,932
Date: 16 Dec 2025
Ownership: Direct
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 30,932
Exercise price: $0.000000
Footnotes: F1, F5, F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.

Footnote F2

On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.

Footnote F3

The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.

Footnote F4

The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.

Footnote F5

On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants").

Footnote F6

The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.

Footnote F7

Conversion Exercise Price of Security is $0.00001

SEC remarks

See Exhibit 24 - Power of Attorney